Feb 12, 2025 11:01AM
Aug 8, 2024 11:03AM
May 2, 2024 11:01AM
Aug 3, 2023 11:01AM
May 19, 2023 12:34PM
May 19, 2023 12:33PM
Feb 22, 2023 11:01AM Genmab Publishes 2022 Annual Report
Nov 9, 2022 11:01AM
Nov 3, 2022 12:45PM
Aug 10, 2022 11:01AM
Jul 18, 2022 10:02AM
Jul 18, 2022 10:01AM
Jun 30, 2022 02:25PM
Jun 30, 2022 02:24PM Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
May 11, 2022 11:01AM
Apr 19, 2022 06:29AM
Feb 16, 2022 11:00AM
Jan 25, 2022 06:30AM
Nov 10, 2021 11:00AM
Oct 19, 2021 06:37AM
Oct 19, 2021 06:29AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Sep 20, 2021 05:00PM
Aug 11, 2021 11:01AM
Jul 21, 2021 06:36AM
Jul 21, 2021 06:31AM
Jun 22, 2021 10:13AM
Jun 22, 2021 10:12AM
May 21, 2021 09:10AM Genmab (GMAB) Announces Janssen has Received Positive CHMP Opinion Recommending DARZALEX Subcutaneous Formulation for Patients with Newly Diagnosed Light-chain Amyloidosis
May 21, 2021 09:08AM
May 5, 2021 11:01AM
Apr 20, 2021 06:34AM
Apr 9, 2021 04:00PM
Feb 23, 2021 11:00AM
Feb 10, 2021 04:05PM
Jan 26, 2021 06:45AM Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
Jan 15, 2021 02:17PM
Nov 4, 2020 11:04AM
Oct 21, 2020 04:50PM
Oct 21, 2020 04:48PM
Oct 13, 2020 06:42AM
Sep 21, 2020 10:20AM
Aug 20, 2020 04:40PM Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Aug 20, 2020 01:33PM
Aug 11, 2020 09:30AM
Aug 10, 2020 06:16PM
Jul 31, 2020 03:38PM
Jul 16, 2020 06:43AM
Jun 29, 2020 04:30PM
Jun 29, 2020 04:29PM Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Jun 4, 2020 09:42AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All